Fig. 3From: A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancerChanges in tumor markers. a Changes in CEA. b Changes in CA19-9, SPAN-1 and DUPAN-2. CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; SPAN-1, s-pancreas antigen-1; DUPAN-2, duke pancreatic monoclonal antigen type 2Back to article page